Valneva rises

Valneva’s chikungunya vaccine wins UK approval
Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults. France-based Valneva has also submitted label extension applications in the US,
Valneva jumps 19% after chikungunya vaccine wins UK approval
Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per
Valneva rises after U.K. approval of chikungunya vaccine
Shares of Valneva (NASDAQ:VALN) traded higher on Wednesday after the French biotech announced that the U.K.’s Medicines and Healthcare Products Regulatory Agency granted marketing authorization for its chikungunya vaccine.
Valneva receives authorisation for world’s first Chikungunya vaccine
Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is indicated for active immunisation for the prevention of disease caused by Chikungunya virus (CHIKV) in individuals 18 years of age and older.
MHRA grants Valneva marketing authorization for chikungunya vaccine
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United
Valneva announces positive outcomes from chikungunya vaccine trial
Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents.
Valneva shares positive phase 3 results for chikungunya vaccine in adolescents
Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to 17 years. The vaccine, Ixchiq, is already approved in the US, Europe and Canada to prevent the mosquito-borne viral disease in individuals aged 18 years and older.
UK grants approval for Valneva’s chikungunya vaccine
French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), marking the fourth regulatory approval for the world’s first vaccine against the virus.
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada 4 in adults 18 years of age and older.
Valneva Is A 'Buy' As A First-Mover In Chikungunya
Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...
FiercePharma2d
Valneva snares $33M contract to supply US with Japanese encephalitis vaccine
While much of Valneva's focus these days is centered on its landmark vaccine for chikungunya virus, the French immunization specialist's catalog of older shots continues to serve up fresh governmen | ...
BioPharma Dive11h
Amgen obesity drug on hold; Regeneron sets first dividend
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
What is HC Wainwright’s Estimate for Valneva Q1 Earnings?
Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Valneva in a research note ...
Valneva (0OB3) Gets a Buy from Kepler Capital
In a report released on January 31, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a ...